INNOVADERM-RESEARCH
Innovaderm is Pleased to Announce the Acquisition of Excelsus Statistics
Innovaderm, a leading CRO in dermatology, has expanded its biometrics capacity following the acquisition of Excelsus Statistics, a Montreal-based company specialized in biostatistical and SAS programming services with a special expertise in adaptive trial design, as well as activities in many different therapeutic areas.
“We are pleased to grow our Biometrics team with the addition of new talent,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm has a reputation for excellence in clinical research in dermatology, as well as attracting committed professionals in the field. Our collective expertise will allow us to offer biometrics services across different therapeutic areas and fulfill the growing needs of our clients.”
Since 2014, Excelsus Statistics has served as a collaborator in many studies managed by Innovaderm. The integration of the two companies will allow Excelsus Statistics’ existing clients to now have access to full CRO services including data management in addition to statistical services.
“I am very excited because our experience in statistics and study management coupled with Innovaderm’s international reputation is a win-win situation,” says Diane Potvin, president of Excelsus Statistics. “This is a tremendous opportunity to consolidate resources and drive research forward.”
Innovaderm is a full-service CRO that is known for its excellent in-house data management and biostatistical services. It offers a wide range of biometrics services including protocol design, writing of statistical analysis plans, statistical programming, interpretation and reporting of data for clinical trial reports and publications, and statistical and strategic consulting for product development.
For more information on Innovaderm’s services, visit our website .
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IL-WALDOM-ELECTRONICS8.8.2022 20:32:07 CEST | Press release
Waldom Electronics Announces New Advisory Board
NY-SERMO8.8.2022 16:02:13 CEST | Press release
Sermo Barometer Reveals Growing Concern Among Global Physicians Regarding Monkeypox
MA-ADVENT-TECHNOLOGIES8.8.2022 15:02:09 CEST | Press release
Advent Technologies and the Greek Natural Gas Company, DEPA Commercial, sign MoU to collaborate on Hydrogen Projects
PHARMA-TECH-HOLDING8.8.2022 10:52:05 CEST | Press release
Pharma Tech Holdings SA Obtains a Capital Commitment Agreement of CHF 30 million from Global Investor LDA Capital
SMILE-HAIR-CLINIC8.8.2022 09:32:12 CEST | Press release
Smile Hair Clinic Named 'Hair Transplant Clinic of the Year'
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom